Creatine Supplementation in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial

Carregando...
Imagem de Miniatura
Citações na Scopus
45
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
ALVES, Christiano R. R.
SANTIAGO, Bianca M.
TRITTO, Aline C. C.
ROSCHEL, Hamilton
Citação
ARTHRITIS CARE & RESEARCH, v.65, n.9, p.1449-1459, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective. To investigate the efficacy and safety of creatine supplementation in fibromyalgia patients. Methods. A 16-week, randomized, double-blind, placebo-controlled, parallel-group trial was conducted. Fibromyalgia patients were randomly assigned to receive either creatine monohydrate or placebo in a double-blind manner. The patients were evaluated at baseline and after 16 weeks. Muscle function, aerobic conditioning, cognitive function, quality of sleep, quality of life, kidney function, and adverse events were assessed. Muscle phosphorylcreatine content was measured through P-31 magnetic resonance spectroscopy. Results. After the intervention, the creatine group presented higher muscle phosphorylcreatine content when compared with the placebo group (+80.3% versus -2.7%; P = 0.04). Furthermore, the creatine group presented greater muscle strength than the placebo group in the leg press and chest press exercises (+9.8% and +1.2% for creatine versus -0.5% and -7.2% for placebo, respectively; P = 0.02 and P = 0.002, respectively). Isometric strength was greater in the creatine group than in the placebo group (+6.4% versus -3.2%; P = 0.007). However, no general changes were observed in aerobic conditioning, pain, cognitive function, quality of sleep, and quality of life. Food intake remained unaltered and no side effects were reported. Conclusion. Creatine supplementation increased intramuscular phosphorylcreatine content and improved lower- and upper-body muscle function, with minor changes in other fibromyalgia features. These findings introduce creatine supplementation as a useful dietary intervention to improve muscle function in fibromyalgia patients.
Palavras-chave
Referências
  1. Amital D, 2006, J PSYCHOSOM RES, V61, P663, DOI 10.1016/j.jpsychores.2006.07.003
  2. Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035
  3. Antolic A, 2007, MED SCI SPORT EXER, V39, P816, DOI 10.1249/mss.0b013e318031fac4
  4. Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518
  5. Bennett R, 1996, J MUSCULOSKELET PAIN, V4, P35, DOI 10.1300/J094v04n01_05
  6. Brown LE, 2001, J EXERCISE PHYSL, V4, P21
  7. BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728
  8. Cohen J., 1988, STAT POWER ANAL BEHA
  9. Coplan JD, 2006, PSYCHIAT RES-NEUROIM, V147, P27, DOI 10.1016/j.pscychresns.2005.12.011
  10. CRONHOLM B, 1956, Nord Med, V56, P1612
  11. Dechent P, 1999, AM J PHYSIOL-REG I, V277, pR698
  12. Dechent P, 1999, BIOL PSYCHIAT, V46, P406, DOI 10.1016/S0006-3223(98)00346-1
  13. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  14. Gotshalk LA, 2008, EUR J APPL PHYSIOL, V102, P223, DOI 10.1007/s00421-007-0580-y
  15. Gualano B, 2008, EUR J APPL PHYSIOL, V103, P33, DOI 10.1007/s00421-007-0669-3
  16. Gualano B, 2011, AMINO ACIDS, V43, P519
  17. Gualano B, 2008, AMINO ACIDS, V34, P245, DOI 10.1007/s00726-007-0508-1
  18. Gualano B, 2011, EUR J APPL PHYSIOL, V111, P749, DOI 10.1007/s00421-010-1676-3
  19. Gualano B, 2011, MED SCI SPORT EXER, V43, P770, DOI 10.1249/MSS.0b013e3181fcee7d
  20. Hauser W, 2010, EUR J PAIN, V14, P5, DOI 10.1016/j.ejpain.2009.01.006
  21. Leader A, 2009, ANN NY ACAD SCI, V1173, P829, DOI 10.1111/j.1749-6632.2009.04811.x
  22. MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006
  23. McMorris T, 2007, PHYSIOL BEHAV, V90, P21, DOI 10.1016/j.physbeh.2006.08.024
  24. McMorris T, 2007, AGING NEUROPSYCHOL C, V14, P517, DOI 10.1080/13825580600788100
  25. Mease P, 2007, J RHEUMATOL, V34, P1415
  26. Mease PL, 2009, RHEUM DIS CLIN N AM, V35, P359, DOI 10.1016/j.rdc.2009.06.007
  27. MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
  28. Neves M, 2011, MED SCI SPORT EXER, V43, P1538, DOI 10.1249/MSS.0b013e3182118592
  29. Neves M, 2011, APPL PHYSIOL NUTR ME, V36, P419, DOI [10.1139/h11-014, 10.1139/H11-014]
  30. Ravina B, 2006, NEUROLOGY, V66, P664
  31. Nitrini R, 2004, J INT NEUROPSYCH SOC, V10, P634, DOI 10.1017/S1355617704104062
  32. Park DC, 2001, ARTHRITIS RHEUM, V44, P2125, DOI 10.1002/1529-0131(200109)44:9<2125::AID-ART365>3.0.CO;2-1
  33. Park JH, 1998, ARTHRITIS RHEUM, V41, P406, DOI 10.1002/1529-0131(199803)41:3<406::AID-ART5>3.0.CO;2-L
  34. Poortmans JR, 2005, MED SCI SPORT EXER, V37, P1717, DOI 10.1294/01.mss.0000176398.64189.e6
  35. Poortmans JR, 1999, MED SCI SPORT EXER, V31, P1108, DOI 10.1097/00005768-199908000-00005
  36. Rae C, 2003, P ROY SOC B-BIOL SCI, V270, P2147, DOI 10.1098/rspb.2003.2492
  37. Rawson ES, 2008, PHYSIOL BEHAV, V95, P130, DOI 10.1016/j.physbeh.2008.05.009
  38. Rawson ES, 2011, AMINO ACIDS, V40, P1349, DOI 10.1007/s00726-011-0855-9
  39. Roschel H, 2011, PHYSIOTHERAPY, V97, P350, DOI 10.1016/j.physio.2011.01.007
  40. Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313
  41. Stockler S, 1996, LANCET, V348, P789, DOI 10.1016/S0140-6736(96)04116-5
  42. Tarnopolsky M, 1999, NEUROLOGY, V52, P854
  43. Watanabe A, 2002, NEUROSCI RES, V42, P279, DOI 10.1016/S0168-0102(02)00007-X
  44. WEBB WB, 1976, PERCEPT MOTOR SKILL, V43, P987
  45. WOLFE F, 1990, ARTHRITIS RHEUM, V33, P160, DOI 10.1002/art.1780330203
  46. WOLFE F, 1995, ARTHRITIS RHEUM, V38, P19, DOI 10.1002/art.1780380104
  47. Wolfe F, 1996, RHEUM DIS CLIN N AM, V22, P369, DOI 10.1016/S0889-857X(05)70277-5
  48. Wyss M, 2000, PHYSIOL REV, V80, P1107